Who is Zydus


Zydus Pharmaceuticals (USA) Inc., located in Pennington, New Jersey, has come a long way since its first commercial launch in August 2005. The company currently offers more than 450 SKUs to the US market and is ranked the fifth largest unbranded generic corporation in the US based on dispensed prescriptions (IQVIA, NPA Audit, MAT April 2022). In 2017, Zydus acquired Sentynl Therapeutics Inc., a specialty pharmaceutical company based in Solana Beach, CA. This acquisition has helped Zydus to grow from a generic company focused on solid oral generics to a company that offers more complex dosage forms.

While Zydus has grown tremendously since it entered the US, the company is continuing to look for new ways to bring value to the US market. Zydus is aggressively pursuing franchises it does not exist in today to further its footprint in the lives of patients. The company has launched several products out of its oncology facility and plans on expanding its dermatology and injectable product lines.

With the strength and worldwide reputation of Zydus Lifesciences supporting the US division, Zydus is looking forward to continuing its growth in the US marketplace. As the company focuses its efforts on more challenging and rewarding opportunities, including several first-to-file and 505(b)(2) opportunities, it looks forward to great success in the coming years. To date, Zydus has filed over 120 drug master files (DMFs), received final USFDA approval on 288 Abbreviated New Drug Applications (ANDAs), received tentative USFDA approval on 30 ANDAs, and has 94 ANDAs pending approval with the USFDA. The company also has approximately 250 additional products in various stages of development.

Our Mission

Creating Healthier Communities
Zydus is dedicated to life, in all its dimensions. Our world is shaped by a passion for innovation, commitment to partners and concern for people in an effort to create healthier communities, globally.

A Vision That Unleashes Value
Zydus shall be a leading global healthcare provider with a robust product pipeline; Opening up new pathways through innovation and quality excellence, we shall be a research-based company by the end of 2020.

To learn more, Contact Us.

Our Core Values

Quality. Innovation. Service.
Driven by creativity and innovation, we strive for excellence and to make a difference in the world of pharmaceuticals and healthcare.

Our Acquisition Trail



Sentynl Therapeutics Provided Zydus a platform to enter the specialty distribution market in the US

Zydus Lifesciences Today: A Global, Mid-Sized Pharma Company

Zydus Lifesciences, a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. From formulations to active pharmaceutical ingredients and animal healthcare products to wellness products, Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions.

One of the salient features of Zydus is its rich history and lineage. The origin of the company dates all the way back to the 1950s. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.

In 1995, the group was restructured and thus was formed Cadila Healthcare (later known as Zydus Lifesciences) under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 11600 crores in FY18. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe.

60+ Years

Operational Experience

$1 billion +

Global Revenues

20+ Manufacturing Sites

Producing >12 billion pills annually